
Opinion|Videos|May 29, 2025
Clinical Experience With CSAI for Parkinson Disease
Panelists discuss how their clinical experience with continuous subcutaneous infusion therapies has informed their approach to integrating these treatments into existing regimens, including strategies for medication adjustments and valuable lessons from European clinical practice that could benefit US clinicians.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Clinical Experience With Infusion Systems
Experience with Continuous Subcutaneous Apomorphine Infusion (CSAI) and Other Infusions:
- Learning curve for both clinicians and patients
- Initial intensive monitoring period crucial for success
- Importance of team-based approach to management
- Technical challenges with devices gradually resolved with experience
- Patient selection critically impacts outcomes
Incorporation Into Existing Treatment Plans:
- Gradual introduction alongside existing oral medications
- Individualized titration based on symptom response
- Maintenance of morning oral medication is often beneficial
- Combination with low-dose oral therapy for overnight symptom control
- Careful monitoring during transition period
Adjusting Levodopa and Other Medications:
- Systematic reduction based on observed response to infusion
- Typically, 30% to 50% reduction in oral levodopa dose initially
- Complete elimination of certain adjunctive medications possible
- Individual titration based on symptom diaries and clinical assessment
- Maintaining minimum necessary oral medications to optimize benefit-risk ratio
Lessons From European CSAI Experience:
- Importance of dedicated nursing support for successful implementation
- Need for thorough patient education and expectation management
- Value of standardized protocols for initiation and troubleshooting
- Strategic management of common adverse effects improves adherence
- Multidisciplinary approach improves outcomes and patient satisfaction
Advertisement
Related to this article

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
2
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
5

